GenomeDx Announces Launch of Decipher GRIDTM and Partnership with Sidney Kimmel Cancer Center to Accelerate Innovation in Urologic Cancer Patient Care

GenomeDx Announces Launch of Decipher GRIDTM and Partnership with Sidney Kimmel Cancer Center to Accelerate Innovation in Urologic Cancer Patient Care

New program shares genomic information to enhance individualized care of patients suffering from urologic cancers

San Diego, May 12, 2015 – GenomeDx Biosciences today announced the launch of the Decipher® Genomics Resource Information Database (Decipher GRIDTM), a clinical genomics data sharing program that unites patient registries from leading cancer centers with GenomeDx's full genome profiling platform. The Sidney Kimmel Cancer Center at Thomas Jefferson University is the first institution to partner with GenomeDx to access this ground-breaking program, with additional world-renowned medical centers expected to participate by end of year.

The Decipher GRIDTM allows institutions to bring extensive genomic data to patients participating in clinical registries and trials for new treatments. Centers such as the Sidney Kimmel Cancer Center at Thomas Jefferson University will gain real-time genomic insight into the biology of cancer to customize treatments for their patients. Over time, the program will apply a 'big data' genomic approach to systematically study large populations in order to deepen our understanding of urologic cancers.

"GenomeDx has built the world's largest genomic database for prostate and bladder cancer," said Doug Dolginow, MD, CEO of GenomeDx. "Through the Decipher GRID, we are marrying the power of genomic information with prospective clinical outcomes for patients. We are collecting over a million data points from each patient and have the ability to analyze and leverage those data to ask questions that can ultimately lead to a better understanding of how we manage and treat these patients at every critical decision point. This program has the potential to create new information that will completely redefine our understanding of the biology of prostate and other urologic cancers."
"Decipher GRID adds a wealth of information for researchers that could help us develop better treatments for these diseases. As a field, we are only beginning to understand the complexity of prostate cancer and how this can be leveraged to provide patients with more effective and less toxic treatments," said Robert B. Den, Assistant Professor of Radiation Oncology and Cancer Biology, Thomas Jefferson University. "Partnering with GenomeDx to provide our patients with the Decipher GRID is another example of the innovative approach provided at the world class Thomas Jefferson University multidisciplinary GU clinic."
"Bringing genomics into the clinical arena distinguishes the Sidney Kimmel Cancer Center prostate program," said Adam P. Dicker, Professor and Chair of Radiation Oncology, Thomas Jefferson University. "We are excited about the innovative partnership with GenomeDx and the potential this has for the way we manage and treat our patients with prostate cancer."

The program is being launched initially for men with prostate cancer and is expected to expand into other urologic cancers. Patients participating in the program will all benefit from initial testing with the Decipher Prostate Cancer Classifier (www.DecipherTest.com). As a part of standard clinical testing, whole genome information will be collected allowing for customized genomic reporting for clinicians and their patients, providing additional research insights that may be important for clinical care. As the program grows, GenomeDx will collaborate on large-scale clinical studies to harness the vast amounts of genomic data stored in the Decipher GRID.

The Decipher GRIDTM leverages the world's largest clinically annotated urologic cancer genomic expression database, built up over 7 years of global research with thousands of patients studied using the Decipher test platform. Data sharing through the GRID provides cancer centers an innovative opportunity to translate advances in genomics to individualize the care of patients suffering from urologic cancers. The ability to mine the GRID for genomic insights may help identify more appropriate treatment strategies or clinical trials of novel agents for patients at the highest risk of developing metastasis and dying of their disease.

About Decipher®

The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.

Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.
Learn more at: www.DecipherTest.com and follow Decipher on Twitter @DecipherTest and on Facebook.

About GenomeDx Biosciences

GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.genomedx.com and follow us on Twitter @GenomeDx, Facebook, LinkedIn and YouTube.

Media Contact:

Ian Stone
Canale Communications
619-849-5388
[email protected]

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.